Narwhal Capital Management Buys 15,755 Shares of Johnson & Johnson $JNJ

Narwhal Capital Management increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 19.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,371 shares of the company’s stock after acquiring an additional 15,755 shares during the quarter. Johnson & Johnson comprises approximately 1.3% of Narwhal Capital Management’s investment portfolio, making the stock its 18th biggest holding. Narwhal Capital Management’s holdings in Johnson & Johnson were worth $17,869,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Clark Asset Management LLC increased its stake in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the period. Treasurer of the State of North Carolina grew its holdings in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after buying an additional 94,957 shares in the last quarter. Avanza Fonder AB increased its position in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after buying an additional 6,566 shares during the period. Talbot Financial LLC lifted its holdings in shares of Johnson & Johnson by 4.6% during the third quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after buying an additional 6,143 shares in the last quarter. Finally, Winnow Wealth LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $295,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on JNJ shares. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Bank of America raised their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Raymond James Financial boosted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Scotiabank began coverage on Johnson & Johnson in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price objective on the stock. Finally, Stifel Nicolaus lifted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $209.79 on Tuesday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $215.18. The stock has a market capitalization of $505.45 billion, a price-to-earnings ratio of 20.25, a price-to-earnings-growth ratio of 2.10 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company’s 50 day simple moving average is $203.34 and its 200 day simple moving average is $185.38.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.